Palferman T G, Webley M
Department of Rheumatology, Yeovil District Hospital, Higher Kingston, Somerset.
Eur J Rheumatol Inflamm. 1991;11(2):23-9.
Forty-two patients with ankylosing spondylitis were entered into a double-blind study to compare treatment with indomethacin and a new non-steroidal anti-inflammatory drug, nabumetone. Clinical, laboratory and side-effect profiles were measured over a three month period. Both drugs were effective in relieving pain and morning stiffness, indomethacin was better in alleviating general stiffness, nabumetone resulted in less side-effects. Objective measurements of spinal movements revealed no difference between the two drugs. Nabumetone, available as Relifex, appears as effective as indomethacin in relieving the symptoms of ankylosing spondylitis and is possibly better tolerated.
42例强直性脊柱炎患者进入一项双盲研究，以比较吲哚美辛与一种新的非甾体抗炎药萘丁美酮的治疗效果。在三个月的时间里对临床、实验室指标及副作用情况进行了测量。两种药物在缓解疼痛和晨僵方面均有效，吲哚美辛在减轻全身僵硬方面效果更好，萘丁美酮的副作用更少。对脊柱活动的客观测量显示两种药物之间没有差异。作为瑞力芬（Relifex）上市的萘丁美酮在缓解强直性脊柱炎症状方面似乎与吲哚美辛一样有效，并且可能耐受性更好。
